• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.03% Nasdaq Up0.17%

    Rexahn Pharmaceuticals, Inc. (RNN)

    -NYSE MKT
    0.71 0.02(2.08%) Dec 24, 1:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Rexahn Pharmaceuticals, Inc.
    15245 Shady Grove Road
    Suite 455
    Rockville, MD 20850
    United States - Map
    Phone: 240-268-5300
    Fax: 240-268-5310
    Website: http://www.rexahn.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:16

    Business Summary 

    Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer. The company has three clinical stage oncology candidates: Archexin, RX-3117, and SupinoxinTM (RX-5902), as well as a pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. The company is based in Rockville, Maryland.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Rexahn Pharmaceuticals, Inc.

    Key Executives 
     PayExercised
    Dr. Chang H. Ahn Ph.D., 62
    Founder, Chairman and Chief Scientist
    319.00K0.00
    Dr. Peter D. Suzdak Ph.D., 55
    Chief Exec. Officer and Director
    380.00K0.00
    Mr. Rakesh Soni , 58
    Pres and Chief Operating Officer
    268.00K0.00
    Dr. Tae Heum Jeong D. Mgt., 43
    Chief Financial Officer, Principal Accounting Officer, Sr. VP and Sec.
    270.00K0.00
    Dr. Stephen M. Stahl M.D., Ph.D.,
    Consultant
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders